Top 8 Companies in the Breast Cancer Treatment Market in 2025

The global breast cancer treatment market attained a value of USD 22.49 Billion in 2024. The market is likely to grow at a rate of 10.10% during the forecast period of 2025-2034. The market growth is driven by the growing demand for diagnostics and therapeutics and the market is anticipated to be worth USD 58.87 Billion by 2034.

Breast cancer is a deadly cancer among women in which abnormal breast cells grow out of control and form tumours. If left untreated it turns metastatic, which can be life-threatening. According to the World Health Organization, in 2022, 2.3 million women were diagnosed with breast cancer and 670,000 women reportedly died from it. The increasing prevalence and incidence of breast cancer in both developing and developed nations is also boosting market growth. According to Cancer Australia, in 2021, the risk of breast cancer was estimated to be 1 in 15 individuals by the age of 85 . Thus, the rising cases of breast cancer have directly influenced the demand for breast cancer treatment, thereby attributing to the market growth.

The growing research and development activities by the strategic key market players are expected to accelerate the launch and development of novel therapeutic products, that will further boost the market during the forecast period. The rising number of mergers and acquisitions among the major pharmaceutical companies is also expected to bolster the breast cancer treatment market growth.

The FDA plays an important role in market growth due to the high credibility it adds to the product. FDA is a prerequisite for a drug to be marketed and sold in the United States and other regions. The market is witnessing a significant number of FDA approvals focused on the treatment of patients suffering from breast cancers, fuelling market demand.

For instance, in April 2024, HLX02, a trastuzumab biosimilar was approved by the FDA as an adjuvant treatment for HER2-overexpressing breast cancer, HER2-overexpressing metastatic breast cancer, and HER2-overexpressing metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. The approval was based on a series of head-to-head trials with HLX02, including comparative quality analytical data, a phase 1 pharmacokinetic similarity trial, and a global, multicenter, phase 3 trial where HLX02 showed high similarity about trastuzumab about quality, safety, and efficacy.

In February 2024, Arvinas, Inc. and Pfizer Inc. announced the U.S. Food and Drug Administration (FDA) Fast Track designation to the investigation of vepdegestrant (ARV-471) for monotherapy in the treatment of adults with estrogen receptor (ER) positive/human growth epidermal growth factor 2 (HER2) negative (ER+/HER2-) locally advanced or metastatic breast cancer which was used to be treated with endocrine-based therapy. Vepdegestrant is a novel oral PROteolysis Targeting Chimera (PROTAC®) ER degrader that is being jointly developed by Arvinas and Pfizer.

Additionally, in June 2024, the FDA approved a new drug application (NDA) for Tepylute (formerly SH-105), a ready-to-dilute formulation that is used to treat adenocarcinoma of the breasts and ovaries. Tepylute is a liquid form of the standard-of-care agent, thiotepa. The new formulation of the agent removes the need for complex and time-consuming reconstitution, allowing for consistent dosing accuracy.

Top Companies Leading the Breast Cancer Treatment Market in 2025

1. Mylan N.V (Viatris Inc.)

Viatris is a global healthcare company, that was formed through the merger of Mylan N.V. and Upjohn, a division of Pfizer. The company offers a diverse portfolio of prescription medicines, including biosimilars . The company focuses on providing affordable generic options and biosimilars, such as trastuzumab.

2. AstraZeneca

AstraZeneca, a British-Swedish multinational pharmaceutical company, is known for its strong focus on oncology. The company’s portfolio includes targeted therapies like Lynparza (olaparib) and Enhertu (trastuzumab deruxtecan), which are used in the treatment of specific types of breast cancer.

3. Celltrion Inc.

Celltrion is a South Korean biopharmaceutical company, specializes in the development of biosimilars and biologics. The company has developed biosimilars like Herzuma (a trastuzumab biosimilar) for the treatment of HER2-positive breast cancer, expanding access to biologic therapies globally.

4. Bristol-Myers Squibb Company

Bristol-Myers Squibb (BMS) is an American pharmaceutical company with a strong emphasis on oncology and immunotherapy. The company's portfolio includes immuno-oncology drugs like Opdivo  (nivolumab) and combination therapies aimed at enhancing the immune response against breast cancer cells.

5. Fresenius Kabi AG

Fresenius Kabi, a global healthcare company based in Germany, specializes in lifesaving medicines and technologies. The company offers supportive care products, including intravenous fluids, parenteral nutrition, and generics that support chemotherapy regimens.

6. Eisai Co.

Eisai, a Japanese pharmaceutical company, focuses on oncology and neurology. The company is known for Halaven (eribulin mesylate), a microtubule dynamics inhibitor used in the treatment of metastatic breast cancer, particularly in patients who have previously received chemotherapy.

7. Baxter

Baxter, an American healthcare company, is primarily known for its expertise in medical devices and critical care. The company’s contribution focuses on providing supportive care products, including intravenous solutions, drug delivery systems, and anesthesia products used during surgical interventions.

8. GSK plc

GSK, a British multinational pharmaceutical company, is involved in the development of vaccines and medicines. The company’s portfolio includes Tykerb (lapatinib), a targeted therapy used in combination with other drugs for HER2-positive breast cancer, particularly in patients who have not responded to other treatments.